MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILIT, Israel, Aug. 02, 2022 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or the “Firm”), a number one producer of robotic medical know-how for folks with decrease extremity disabilities, at present introduced the outcomes of the Firm’s 2022 Annual Assembly of Shareholders (the “Annual Assembly”) based mostly on the ultimate tabulation of votes licensed by an impartial Inspector of Elections. On the Annual Assembly, shareholders voted to reelect Chief Government Officer Larry Jasinski, Dr. John William Poduska and Randel Richner to the Board of Administrators (the “Board”). Shareholders didn’t vote to approve the proposals put forth by Inventive Worth Capital Restricted Partnership (“CVC”).
To advance shareholders’ pursuits, the Board has determined to nominate Hadar Levy to the Board. Mr. Levy, who has additive expertise in company finance and the broader healthcare sector, has agreed to right away be a part of as a director. The Board thanks CVC for placing forth Mr. Levy as a candidate. Over the following yr, the Firm additionally intends to cut back the dimensions of its Board and proceed to judge director refreshment alternatives.
Jeff Dykan, Chairman of ReWalk’s Board, commented:
“We’re grateful to our shareholders for his or her assist on the Annual Assembly and respect the constructive dialogue we’ve had with a lot of them within the previous months. With the addition of Hadar, we imagine our Board possesses the right combination of important talent units and backgrounds which might be instantly relevant to the Firm’s wants. As we strategy key milestones within the near-term, we stay up for continued engagement with our shareholders. We stay dedicated to enhancing shareholder worth by pursuing elevated entry to wearable robotic exoskeletons by means of expanded reimbursement protection within the U.S. and Germany and can present updates as applicable.”
Hadar Levy commented:
“Enhancing folks’s lives by means of commercializing novel applied sciences has all the time been a driving drive in my profession, and ReWalk has finished a wonderful job of growing and acquiring regulatory clearances for its modern merchandise. I’m honored to affix the corporate’s Board and stay up for working with my fellow administrators and the manager administration staff with the intention to obtain the Firm’s long-term strategic aims and improve shareholder worth.”
The ultimate outcomes of the Annual Assembly and all related data can be reported on a Type 8-Okay that can be filed with the U.S. Securities and Alternate Fee.
About Hadar Levy
Mr. Levy began his profession at Deloitte LLP, and, since then, has had an intensive profession within the medical machine business. He has served in key positions at GE Healthcare, Notal Imaginative and prescient, Amdocs and BrainsWay, the place he led monetary and commercialization actions and oversaw the implementation of progress and growth of key merchandise. Mr. Levy holds a BA in Accounting and Economics, an LLM diploma from Bar-Ilan College, and is a Licensed Public Accountant.
About ReWalk Robotics Ltd.
ReWalk Robotics Ltd. develops, manufactures and markets wearable robotic exoskeletons for people with decrease limb disabilities on account of spinal wire harm or stroke. ReWalk’s mission is to essentially change the standard of life for people with decrease limb incapacity by means of the creation and growth of market main robotic applied sciences. Based in 2001, ReWalk has headquarters within the U.S., Israel and Germany. For extra data on the ReWalk programs, please go to rewalk.com.
ReWalk® and ReStore® are registered logos of ReWalk Robotics Ltd. in america and different jurisdictions.
Ahead Wanting Statements
Along with historic data, this press launch accommodates forward-looking statements inside the which means of the U.S. Personal Securities Litigation Reform Act of 1995, Part 27A of the U.S. Securities Act of 1933, and Part 21E of the U.S. Securities Alternate Act of 1934. Such forward-looking statements might embody projections relating to ReWalk’s future efficiency and different statements that aren’t statements of historic truth and, in some circumstances, could also be recognized by phrases like “anticipate,” “assume,” “imagine,” “proceed,” “might,” “estimate,” “anticipate,” “intend,” “might,” “plan,” “potential,” “predict,” “venture,” “future,” “will,” “ought to,” “would,” “search” and related phrases or phrases. The forward-looking statements contained on this press launch are based mostly on administration’s present expectations, that are topic to uncertainty, dangers and modifications in circumstances which might be tough to foretell and plenty of of that are outdoors of ReWalk’s management. Vital elements that would trigger ReWalk’s precise outcomes to vary materially from these indicated within the forward-looking statements embody, amongst others: uncertainties related to future scientific trials and the scientific growth course of, the product growth course of and FDA regulatory submission evaluation and approval course of; the opposed impact that the COVID-19 pandemic has had and should proceed to have on the Firm’s enterprise and outcomes of operations; ReWalk’s skill to have enough funds to fulfill sure future capital necessities, which might impair the Firm’s efforts to develop and commercialize present and new merchandise; ReWalk’s skill to keep up compliance with the continued itemizing necessities of the Nasdaq Capital Market and the danger that its abnormal shares can be delisted if it can’t accomplish that; ReWalk’s skill to keep up and develop its status and the market acceptance of its merchandise; ReWalk’s skill to attain reimbursement from third-party payors, together with CMS, for its merchandise; ReWalk’s restricted working historical past and its skill to leverage its gross sales, advertising and coaching infrastructure; ReWalk’s expectations as to its scientific analysis program and scientific outcomes; ReWalk’s expectations relating to future progress, together with its skill to extend gross sales in its present geographic markets and increase to new markets; ReWalk’s skill to acquire sure parts of its merchandise from third-party suppliers and its continued entry to its product producers; ReWalk’s skill to enhance its merchandise and develop new merchandise; ReWalk’s compliance with medical machine reporting laws to report opposed occasions involving the Firm’s merchandise, which might end in voluntary corrective actions or enforcement actions reminiscent of necessary recollects, and the potential impression of such opposed occasions on ReWalk’s skill to market and promote its merchandise; ReWalk’s skill to realize and preserve regulatory approvals; ReWalk’s skill to keep up sufficient safety of its mental property and to keep away from violation of the mental property rights of others; the danger of a cybersecurity assault or breach of the Firm’s IT programs considerably disrupting its enterprise operations; ReWalk’s skill to make use of successfully the proceeds of its choices of securities; and different elements mentioned below the heading “Threat Components” in ReWalk’s annual report on Kinds 10-Okay and 10-Okay/A for the yr ended December 31, 2021 filed with the SEC and different paperwork subsequently filed with or furnished to the SEC. Any forward-looking assertion made on this press launch speaks solely as of the date hereof. Components or occasions that would trigger ReWalk’s precise outcomes to vary from the statements contained herein might emerge once in a while, and it’s not doable for ReWalk to foretell all of them. Besides as required by regulation, ReWalk undertakes no obligation to publicly replace any forward-looking statements, whether or not on account of new data, future developments or in any other case.
Michael Verrechia / Eric Kamback, 203-658-9400
firstname.lastname@example.org / email@example.com
Longacre Sq. Companions
Greg Marose / David Reingold
firstname.lastname@example.org / email@example.com